Loading
A phase 1/2 trial of AB-3028 in prostate cancer, run by Arsenal Biosciences, Inc., active and no longer recruiting.
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC) is a phase 1/2 interventional study registered as NCT07285694 by Arsenal Biosciences, Inc., with 190 participants enrolled, started 2026-01-09 and due to reach its primary completion in 2029-05. Interventions recorded: AB-3028.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Arsenal Biosciences and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/